<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000450.v1.p1" parentStudy="phs000450.v1.p1" createDate="2012-01-27" modDate="2012-03-02">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Todd Golub</td><td>Broad Institute, Cambridge MA, Dana Farber Cancer 			Institute, Boston MA</td></tr>
		<tr><td>Principal Investigator</td><td>Jens Lohr</td><td>Broad Institute, Cambridge MA, Dana Farber Cancer 			Institute, Boston MA</td></tr>
		<tr><td>Principal Investigator</td><td>James Cerhan</td><td>Mayo Clinic, Rochester MN</td></tr>
		<tr><td>Funding Source</td><td>Carlos Slim Health Institute, Mexico City, Mexico</td><td>Slim Initiative for Genomic Medicine</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Whole Exome Sequencing of Diffuse Large B-Cell Lymphoma</StudyNameEntrez>
	<StudyNameReportPage>Whole Exome Sequencing of Diffuse Large B-Cell Lymphoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
		<StudyType>Tumor</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>We performed massively parallel whole exome sequencing of 55 primary tumor samples from patients with diffuse large B cell lymphoma (DLBCL) and matched normal tissue. We identified recurrent mutations in genes that are well known to be functionally relevant in DLBCL, as well as in genes for which a functional role in DLBCL has not been previously suspected. Significantly mutated genes include MYD88, CARD11, EZH2, CREBBP, as well as MEF2B, MLL2, BTG1, GNA13, ACTB, P2RY8, PCLO and TNFRSF14. Analysis of somatic mutations in patients with DLBCL also revealed that BCL2 mutations commonly occur in patients with BCL2/IgH rearrangements as a result of somatic hypermutation normally occurring at the IgH locus. The BCL2 point mutations are primarily synonymous, likely caused by AID-mediated somatic hypermutation, and those non-synonymous mutations that are observed tend to be found outside of the functionally important BH domains of the protein, suggesting that strong negative selection against BCL2 loss-of-function mutations is at play. We further identified genes with mutations that are likely to be functionally relevant despite being mutated at a low rate. These genes include KRAS, BRAF and NOTCH1 as likely drivers of DLBCL pathogenesis in some patients. Our data provide an unbiased view of the landscape of mutations in DLBCL. These data may point towards new targets for the treatment of DLBCL. </p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Jens G. Lohr, Petar Stojanov, Michael S. Lawrence, Daniel 			Auclair, Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, 			Birgit Knoechel, Yan W. Asmann, Susan L. Slager, Anne J. Novak, 			Ahmet Dogan, Stephen M. Ansell, Brian K. Link, Lihua Zou, 			Joshua Gould, Gordon Saksena, Nicolas Stransky1, Claudia 			Rangel-Escare&#241;o, Juan Carlos Fernandez-Lopez, Alfredo 			Hidalgo-Miranda, Jorge Melendez-Zajgla, Enrique 			Hern&#224;ndez-Lemus, Angela Schwarz-Cruz y Celis, Ivan 			Imaz-Rosshandler, Akinyemi I. Ojesina, Joonil Jung; Chandra S. 			Pedamallu, Ami S. Bhatt, Eric S. Lander, Thomas M. Habermann, 			James R. Cerhan, Margaret A. Shipp, Gad Getz, Todd R. 			Golub" title="Discovery and Prioritization of Somatic Mutations in DLBCL 			by Whole Exome Sequencing" journal="Proceedings of the National Academy of Sciences --In 			Press"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Diffuse Large B-Cell Lymphoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Todd Golub</AttName>
			<Institution>Broad Institute, Cambridge MA, Dana Farber Cancer 			Institute, Boston MA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Jens Lohr</AttName>
			<Institution>Broad Institute, Cambridge MA, Dana Farber Cancer 			Institute, Boston MA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>James Cerhan</AttName>
			<Institution>Mayo Clinic, Rochester MN</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Carlos Slim Health Institute, Mexico City, Mexico</AttName>
			<Institution>Slim Initiative for Genomic Medicine</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="NPU" longName="Non-Profit Use Only"/>
		<ConsentGroup groupNum="2" shortName="BLDO" longName="Blood and Lymph Disorders Only"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>eNCI DAC</DacName>
      <DacFullName>Extramural NCI Data Access Committee</DacFullName>
      <DacEmail>ncidac@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>301-435-5477</DacFax>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000450.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000450.v1.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000450.v1.p1" FileName="DLBCL_DUC_1.25.2012.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Non-Profit Use Only</ConsentName>
        <ConsentAbbrev>NPU</ConsentAbbrev>
        <UseLimitation>The data shall be used for research purposes only and should NOT be made available to commercial entities.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Blood and Lymph Disorders Only</ConsentName>
        <ConsentAbbrev>BLDO</ConsentAbbrev>
        <UseLimitation>Data use is restricted to the study of blood or lymph disorders.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
